metastatic colorectal cancer
Conditions
Interventions
Sponsors
The Second Affiliated Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Age=18 years at the time of enrollment for the prospective cohort or at the time of 2nd line treatment for the retrospective cohort; 2. Histologically or cystologically confirmed diagnosis of recurrent/metastatic colorectal cancer previously treated with 1 or 2 systemic therapy(ies); 3. Genetic testing report confirming the presence of BRAF V600E mutation in tumor tissues; 4. Understand the content of the trial protocol and sign the informed consent form (ICF can be waived under the Ethics Committee agreement).
Exclusion criteria
Exclusion criteria: 1. The diagnosis of colorectal cancer is accompanied by other major cancers; 2. Participated in clinical trials of other intervention drugs during 1st or 2nd line treatment; 3. The patient or his family members do not agree to participate in this study; 4. ls participating in other clinical trials; 5. According to the judgment of the investigator, there are other conditions that are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Describe the treatment path of the target population; | — |
Secondary
| Measure | Time frame |
|---|---|
| The therapeutic effect was evaluated by disease progression, including overall survival , progression free survival and objective remission rate;Demographic information and clinical characteristics of the target population were described;Describe the major adverse effects of treatment (CTCAE levels 2-5, AE/SAE/irAE);EQ5D scale was used to evaluate the progress of quality of life of the target population;Describe patients' expenditure on healthcare resource use from a whole-society perspective; | — |
Countries
China
Contacts
Public ContactKefeng Ding
Outcome results
None listed